Platinum based chemoradiotherapy is the standard of care for inoperable non-small cell lung cancer (NSCLC). With evidence that NSCLC can have a dose dependent response with stereotactic ablative radiotherapy (SABR), we hypothesize that a SABR boost on residual tumor treated with chemoradiotherapy could increase treatment efficacy. The purpose of this study was to determine feasibility of such an approach.
from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2Exm3Xj
Δευτέρα 9 Απριλίου 2018
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objectives Greece is one of the leading tobacco-producing countries in European Union, and every year over 19 000 Greeks die from tobacco-at...
-
Objectives Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreation...
-
Abstract Background Mature T-cell and natural killer (NK)-cell lymphomas compose a heterogeneous group of non-Hodgkin lymphomas, and ext...
-
Objective To describe the prevalence and severity of diabetic retinopathy (DR) and sight-threatening DR (STDR) among Chinese adults with dia...
-
Introduction Multimorbidity (MM) refers to the coexistence of two or more chronic conditions within one person, where no one condition is co...
-
Background Hepatitis B virus (HBV) transmission is known to occur through direct contact with infected blood. There has been some suspicion ...
-
In Rwanda, the prevalence of viral hepatitis (HCV) is poorly understood. The current study investigated the prevalence and risk factors of H...
-
Related Articles Three job stress models and their relationship with musculoskeletal pain in blue- and white-collar workers. J Psycho...
-
Background The health hazards associated with the use of smokeless tobacco (SLT) are similar to those of smoking. However, unlike smoking, l...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου